Ailux Antibody Drug Discovery Platform

Ailux is a biologics innovation company dedicated to developing advanced biotherapeutics through AI-powered solutions. By integrating proprietary computational models with state-of-the-art wet lab capabilities, Ailux aims to tackle previously undruggable targets and design molecules with novel therapeutic profiles. The platform is designed for biopharmaceutical researchers, drug discovery teams, and strategic partners seeking to accelerate the development of next-generation antibody-based medicines.

As a subsidiary of XtalPi, Ailux has established strategic collaborations with leading pharmaceutical companies including Lilly, UCB, and Janssen Biotech, underscoring the platform's industry validation and broad applicability across biologics discovery and development.

End-to-End AI-Driven Platform

• Delivers unique value across the full drug discovery workflow, from comprehensive hit generation through to next-generation lead optimization.
• Unlocks advanced engineering possibilities and maximizes therapeutic differentiation at each stage of development.
• Recognized for solving the most challenging molecular design problems at scale.
• Provides a validated path to deliver novel disease-modifying mechanisms for difficult-to-treat conditions.

Industry-Leading AI Models and AtlaX™ Database

• The platform is built upon three industry-leading foundational AI models, guided by emerging molecular design concepts.
• At the core of these models is AtlaX™, a comprehensive, multi-modal proprietary biologics database.
• AtlaX™ intentionally incorporates both positive data and negative outcomes — including molecules with poor developability — creating a robust foundation for training large-scale generative and predictive models with greater accuracy and relevance.
• The AI models are continuously applied to design advanced biologics that address challenging biological mechanisms.

AI-Enabled Applications

• Hard Targets: Enables discovery and engineering of biologics against previously undruggable or difficult biological targets.
• Advanced Engineering: Supports sophisticated molecular engineering to optimize therapeutic properties and developability.
• Multispecifics Design: Facilitates the design of multispecific antibodies, including bispecific formats, to address complex disease mechanisms.

Therapeutics Pipeline

• Pipeline focuses on cutting-edge antibody-based therapeutics in oncology and immunology.
• Aims to deliver best-in-class potential through multi-pronged differentiation strategies.
• Platform-driven approach enables rapid validation of high-value therapeutic hypotheses.
• Designed to deliver safe and effective clinic-ready candidates efficiently.
• Strong emphasis on differentiated biological and pharmacological mechanisms that address critical unmet patient needs.

Partnering Opportunities

• Ailux actively pursues collaborative partnerships to co-develop transformative medicines.
• Established collaborations include a strategic partnership with Lilly to advance bispecific antibody development, a partnership with UCB on the biologics AI platform, and a license agreement with Janssen Biotech on the biologics AI platform.

Ailux operates as a division of XtalPi, combining deep computational expertise with integrated wet lab capabilities to support end-to-end biologics discovery. The platform is positioned for both internal pipeline advancement and external partnerships with biopharmaceutical organizations seeking differentiated AI-driven biologics solutions.